Spots Global Cancer Trial Database for Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
Official Title: Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.
Study ID: NCT02333565
Study Description
Brief Summary: To determine if combination of everolimus and octreotide exert an anti-tumoral activity in recurrent and/or aggressive meningiomas growth with limited adverse effects.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Assistance Publique Hôpitaux Marseille, Marseille, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
